• Baseline average A1C ∼ 8.1%
  • Baseline average fasting blood sugar ∼ 167 mg/dl
  • Reference [14]
Albiglutide (Alb) monotherapy
52-week, placebo-controlled trial
Placebo
(N=99)
Alb 30 mg weekly
(N=100)
Alb 50 mg weekly
(N=97)
HgA1C (%)
(average change from baseline at 52 weeks)
+0.2% -0.7% -0.9%
Fasting blood sugar (mg/dl)
(average change from baseline at 52 weeks)
+18 -16 -25

  • Albiglutide was dosed 30 mg weekly, and increased to 50 mg weekly if needed
  • Baseline average A1C ∼ 8.1%
  • Baseline average fasting blood sugar ∼ 165 mg/dl
  • Reference [14]
Albiglutide (Alb) added to metformin (≥ 1500 mg/day)
104-week, placebo-controlled trial
Placebo + metformin
(N=100)
Alb 30 - 50 mg weekly + metformin
(N=297)
HgA1C (%)
(average change from baseline at 104 weeks)
+0.3% -0.6%
Fasting blood sugar (mg/dl)
(average change from baseline at 104 weeks)
+10 -18
  • Baseline average A1C - 7.6%
  • Baseline average fasting blood sugar ∼ 162 mg/dl
  • Most patients were being treated with metformin at randomization. Metformin was stopped followed by 2-week washout period.
  • Reference [16]
Dulaglutide (Dul) monotherapy
26-week trial
Dul 0.75 mg weekly
(N=270)
Dul 1.5 mg weekly
(N=269)
HgA1C (%)
(average change from baseline at 26 weeks)
-0.7% -0.8%
Fasting blood sugar (mg/dl)
(average change from baseline at 26 weeks)
-26 -29

  • Baseline average A1C ∼ 8.1%
  • Baseline average fasting blood sugar ∼ 173 mg/dl
  • Reference [16]
Dulaglutide (Dul) added to metformin
52-week trial
Dul 0.75 mg weekly + metformin
(N=281)
Dul 1.5 mg weekly + metformin
(N=279)
HgA1C (%)
(average change from baseline at 52 weeks)
-0.9% -1.1%
Fasting blood sugar (mg/dl)
(average change from baseline at 52 weeks)
-30 -41
  • Baseline average A1C ∼ 7.8%
  • Baseline average fasting blood sugar ∼ 162 mg/dl
  • Reference [1]
Exenatide (Exe) monotherapy
24-week, placebo-controlled trial
Placebo
(N=77)
Exe 5 mcg twice daily
(N=77)
Exe 10 mcg twice daily
(N=78)
HgA1C (%)
(average change from baseline at 24 weeks)
-0.2% -0.7% -0.9%
Fasting blood sugar (mg/dl)
(average change from baseline at 24 weeks)
-5 -17 -19

  • Baseline average A1C ∼ 8.2%
  • Baseline average fasting blood sugar ∼ 172 mg/dl
  • Reference [1]
Exenatide (Exe) added to metformin
30-week, placebo-controlled trial
Placebo + metformin
(N=113)
Exe 5 mcg twice daily + metformin
(N=110)
Exe 10 mcg twice daily + metformin
(N=113)
HgA1C (%)
(average change from baseline at 30 weeks)
0% -0.5% -0.9%
Fasting blood sugar (mg/dl)
(average change from baseline at 30 weeks)
+14 -5 -10

  • Study was open-label
  • Most patients in the study were taking other diabetes medications
  • Baseline average A1C ∼ 8.4%
  • Baseline average fasting blood sugar ∼ 170 mg/dl
  • Reference [15]
Bydureon® vs Byetta®
24-week, head-to-head trial
Bydureon® 2 mg weekly
(N=129)
Byetta® 10 mcg twice daily
(N=123)
HgA1C (%)
(average change from baseline at 24 weeks)
-1.6% -0.9%
Fasting blood sugar (mg/dl)
(average change from baseline at 24 weeks)
-25 -5

  • Baseline average A1C - 8.2%
  • Baseline average fasting blood sugar ∼ 170 mg/dl
  • Reference [2]
Liraglutide (Lir) monotherapy
52-week trial
Lir 1.2 mg once daily
(N=251)
Lir 1.8 mg once daily
(N=246)
HgA1C (%)
(average change from baseline at 52 weeks)
-0.8% -1.1%
Fasting blood sugar (mg/dl)
(average change from baseline at 52 weeks)
-15 -26

  • Baseline average A1C ∼ 8.4%
  • Baseline average fasting blood sugar ∼ 180 mg/dl
  • Reference [2]
Liraglutide (Lir) added to metformin (2000 mg/day)
26-week, placebo-controlled trial
Placebo + metformin
(N=121)
Lir 1.2 mg once daily + metformin
(N=240)
Lir 1.8 mg once daily + metformin
(N=242)
HgA1C (%)
(average change from baseline at 26 weeks)
+0.1% -1.0% -1.0%
Fasting blood sugar (mg/dl)
(average change from baseline at 26 weeks)
+7 -30 -30

  • Baseline average A1C - 8.07%
  • Baseline average fasting blood sugar ∼ 161 mg/dl
  • Reference [21]
Lixisenatide (Lix) monotherapy
12-week placebo-controlled trial
Lix 20 mcg once daily
(N=119)
Placebo once daily
(N=122)
HgA1C (%)
(average change from baseline at 12 weeks)
-0.83% -0.18%
Fasting blood sugar (mg/dl)
(average change from baseline at 12 weeks)
-16 +1.5

  • Baseline average A1C ∼ 8.0%
  • Baseline average fasting blood sugar ∼ 171 mg/dl
  • Reference [21]
Lixisenatide (Lix) added to metformin (average 1955 mg/day)
24-week, placebo-controlled trial
Placebo + metformin
(N=162)
Lix 20 mcg once daily + metformin
(N=161)
HgA1C (%)
(average change from baseline at 24 weeks)
-0.26% -0.72%
Fasting blood sugar (mg/dl)
(average change from baseline at 24 weeks)
-7 -17

  • Baseline average A1C ∼ 8.0%
  • Baseline average fasting blood sugar ∼ 174 mg/dl
  • Reference [21]
Lixisenatide (Lix) vs Exenatide (Exe) in patients taking metformin (average 2039 mg/day)
24-week, open label trial
Lix 20 mcg once daily
(N=318)
Exe 10 mg twice daily
(N=316)
HgA1C (%)
(average change from baseline at 24 weeks)
-0.73% -0.90%
(p=0.0175 for difference between Lix and Exe)
Fasting blood sugar (mg/dl)
(average change from baseline at 24 weeks)
-20 -24

  • Baseline body weight - 204 pounds
  • Most patients were being treated with metformin at randomization. Metformin was stopped followed by 2-week washout period.
  • Reference [16]
Dulaglutide (Dul) monotherapy
26-week trial
Dul 0.75 mg weekly
(N=270)
Dul 1.5 mg weekly
(N=269)
Average change in weight at 26 weeks
(pounds)
-5 -5


  • Baseline weight ∼ 188 pounds
  • Reference [1]
Exenatide (Exe) monotherapy
24-week, placebo-controlled trial
Placebo
(N=77)
Exe 5 mcg twice daily
(N=77)
Exe 10 mcg twice daily
(N=78)
Average change in weight at 24 weeks
(pounds)
-3.3 -5.94 -6.38


  • Study was open-label
  • Most patients in the study were taking other diabetes medications
  • Baseline weight ∼ 210 pounds
  • Reference [15]
Bydureon® vs Byetta®
24-week, head-to-head trial
Bydureon® 2 mg weekly
(N=129)
Byetta® 10 mcg twice daily
(N=123)
Average change in weight at 24 weeks
(pounds)
-5 -3

  • Baseline weight ∼ 204 pounds
  • Reference [2]
Liraglutide (Lir) monotherapy
52-week trial
Lir 1.2 mg once daily
(N=251)
Lir 1.8 mg once daily
(N=246)
Average change in weight at 52 weeks
(pounds)
-4.6 -5.5





Reference [1,2,3,5,16,21]
Gastrointestinal side effect Frequency
(% of patients)
Nausea 12 - 40%
Diarrhea 8 - 15%
Vomiting 5 - 15%